Raymond James Financial
BBNX

Raymond James Financial’s Beta Bionics BBNX Stock Holding History

Raymond James Financial’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Sell
188,883
-9,056
-5% -$134K ﹤0.01% 3415
2025
Q4 		$6.32M Sell
197,939
-6,353
-3% -$170K ﹤0.01% 2319
2025
Q3 		$4.06M Sell
204,292
-12,057
-6% -$212K ﹤0.01% 2616
2025
Q2 		$3.15M Buy
+216,349
New +$3.06M ﹤0.01% 2721

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Raymond James Financial's BBNX Position: Q1 2026 in Review

Raymond James Financial reduced its Beta Bionics (BBNX) stake by 4.6% in Q1 2026, selling an estimated $134K and leaving 188,883 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3415.

Raymond James Financial first reported a position in BBNX in Q2 2025 and has held it in 4 quarters since. The position peaked at $6.32M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Raymond James Financial held 188,883 shares of Beta Bionics worth $1.86M as of Q1 2026.
  • Raymond James Financial sold 9,056 Beta Bionics shares in Q1 2026, an estimated $134K.
  • Beta Bionics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3415 holding.
  • Raymond James Financial first reported a position in Beta Bionics in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Beta Bionics position peaked at $6.32M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.